FDx Advisors Inc. Sells 3,802 Shares of Novo Nordisk A/S $NVO

FDx Advisors Inc. lessened its position in shares of Novo Nordisk A/S (NYSE:NVO) by 36.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,490 shares of the company’s stock after selling 3,802 shares during the quarter. FDx Advisors Inc.’s holdings in Novo Nordisk A/S were worth $448,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NVO. Stone House Investment Management LLC bought a new stake in Novo Nordisk A/S during the 1st quarter worth about $30,000. NewSquare Capital LLC grew its position in shares of Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after buying an additional 282 shares during the period. Disciplina Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 162.3% during the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 297 shares during the last quarter. Dagco Inc. bought a new stake in shares of Novo Nordisk A/S during the first quarter worth approximately $35,000. Finally, Mid American Wealth Advisory Group Inc. acquired a new position in Novo Nordisk A/S in the second quarter valued at approximately $37,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $45.62 on Friday. The stock’s fifty day simple moving average is $55.32 and its 200 day simple moving average is $61.50. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $203.69 billion, a PE ratio of 12.53, a PEG ratio of 2.33 and a beta of 0.65. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. The firm had revenue of $11.74 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. On average, research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have commented on NVO shares. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Hsbc Global Res upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 1st. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday. TD Cowen cut their target price on Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, August 19th. Finally, Rothschild & Co Redburn upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $59.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.